Pre-made Oleclumab benchmark antibody ( Whole mAb, anti-NT5E/CD73 therapeutic antibody, Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Oleclumab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Oleclumab (INN; development code MEDI9447) is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-394-1mg	1mg	3090
GMP-Bios-ab-394-10mg	10mg	Inquiry
GMP-Bios-ab-394-100mg	100mg	Inquiry
GMP-Bios-ab-394-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Oleclumab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody
INN Name	Oleclumab
Target	CD73
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	MedImmune;AstraZeneca;European Network of Gynaecological Oncological Trial Groups;Jules Bordet Institute
Conditions Approved	na
Conditions Active	Non-small cell lung cancer;Ovarian cancer;Breast cancer;Pancreatic cancer;Bladder cancer;Solid tumours
Conditions Discontinued	na
Development Tech	na